Menu

While treating patients is Dr. Hausner’s main focus, he is also involved in research, an important part of working at a teaching university. With more than 100 clinical trials ongoing at the Greenebaum Cancer Center, Dr. Hausner has the opportunity to pursue new modes of inquiry about cancer in pursuit of a cure. This can also be a benefit to patients at Greenebaum, who have access not only to standard methods of treatment like chemotherapy and surgery, but also to experimental drugs and brand new treatment options.

Because the University of Maryland is among the top 25 rated cancer centers in the United States, Dr. Hausner’s office is often a beacon of hope for patients who have been unsuccessful in their treatments elsewhere. An experienced staff allows Dr. Hausner’s office to treat these patients successfully.

In his laboratory, Dr. Hausner studies intercellular communications and the process by which mesothelioma cells spread — a hugely important task if researchers hope to understand and eventually eradicate the disease. And in addition to his work at the University of Maryland, Dr. Hausner also serves as Chief of Hemotology and Oncology at the Baltimore VA Medical Center.

Main Specialty: Oncology

Other Interests & Specialties: General oncology, internal medicine, metastasis, skin cancer, chemotherapy, melanoma, kaposi sarcoma, gastrointestinal cancer, cancer biology, mesothelioma, DNA repair and hematologic oncology.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Internal Medicine, CMS Stage 1 EHR Certification

Education & Experience:

  • Fellowship in Medical Oncology at National Institutes of Health Clinical Center
  • Residency at Charles University
  • Medical Degree from Charles University

Publications:

Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. Molecular and Cellular Pharmacology. Jan 2013;5(1):19-25.

18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma. Clinical Nuclear Medicine. May 2012;37(5):492-494. doi: 10.1097/RLU.0b013e3182478bb5

Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. Annals of Thoracic Surgery. January 2010; 89(1): 200-206; doi: 10.1016/j.athoracsur.2009.08.069

Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Annals of Thoracic Surgery. September 2018; 86(3):903-10. doi: 10.1016/j.athoracsur.2008.06.022

Current Treatment Options and Biology of Peritoneal Mesothelioma: Meeting Summary of the First NIH Peritoneal Mesothelioma Conference. Annals of Oncology. November 2006;17(11):1615-1619. doi: 10.1093/annonc/mdl060″

Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell-lung cancer. Journal of Clinical Oncology. August 2005;23(24):5774-57788. doi: 10.1200/JCO.2005.14.373

High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. Journal of Thoracic and Cardiovascular Surgery. June 2005;129(6):1250-1257. doi: 10.1016/j.jtcvs.2004.12.050

Photo of Dr. Petr F. Hausner

Get Help Contacting Dr. Petr F. Hausner


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe